Previous anti-EGFR (epidermal growth factor receptor) monoclonal antibody or small molecular agent such as gefitinib, erlotinib and so on

Patients with wild-type EGFR

Evidence of interstitial lung diseases

Severe hypersensitivity to icotinib or any of the excipients of this product.

Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study

Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC